Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04344769 · ClinicalTrials.gov registry record
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A clinical trial of Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT04344769 is a study of Autosomal Dominant Polycystic Kidney Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04344769, a study of Autosomal Dominant Polycystic Kidney Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04344769
The ClinicalTrials.gov registry entry for NCT04344769 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04344769 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04344769 about?
NCT04344769 is a clinical study titled "Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)". The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
What is the current status of trial NCT04344769?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2019-10-04. Estimated completion is 2026-12.
What conditions does trial NCT04344769 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.
Who is sponsoring clinical trial NCT04344769?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04344769 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NOX4 and Related Biomarkers in ADPKD
RECRUITING
-
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING · Phase 2
-
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
RECRUITING · Phase 1
-
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
ACTIVE NOT RECRUITING
-
Intrarenal Microvasculature in ADPKD
ACTIVE NOT RECRUITING
-
Role of ROS and cAMP-PKA Biomarkers in ADPKD
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.